Get the Stockscreener App
7.44
1.85%
-0.14
After Hours:
7.44
Arvinas Inc stock is traded at $7.44, with a volume of 1.58M.
It is down -1.85% in the last 24 hours and up +1.09% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$7.58
Open:
$7.51
24h Volume:
1.58M
Relative Volume:
0.67
Market Cap:
$543.06M
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-1.5931
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-5.70%
1M Performance:
+1.09%
6M Performance:
-57.75%
1Y Performance:
-72.96%
1-Day Range:
$7.375
$7.6886
1-Week Range:
$7.375
$8.15
52-Week Range:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.44 | 553.27M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
What catalysts could drive Arvinas Inc. stock higher in 2025Earnings Report Updates That Work - jammulinksnews.com
Arvinas (NASDAQ:ARVN) Stock Price Up 8.6%Here's Why - MarketBeat
Is Arvinas Inc. the Top Chart Pick This WeekBig Return Stock Tips - beatles.ru
Arvinas, Inc. to Host Q2 2025 Financial Results and Corporate Update Webcast on August 6, 2025 - Quiver Quantitative
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire
Protein Degradation Pioneer Arvinas Sets Q2 2025 Earnings Report DateKey Details Inside - Stock Titan
Using data filters to optimize entry into Arvinas Inc.News Based Entry Opportunity Alerts Detected - metal.it
Monaco Asset Management SAM Grows Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
What makes Arvinas Inc. stock price move sharplyHigh Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
Watch for Bullish Crossover in Arvinas Inc.Risk Adjusted Technical Entry Plan Gains Followers - metal.it
Technical Bounce Expected in Arvinas Inc. Next WeekTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Published on: 2025-07-29 03:00:57 - metal.it
ESR1 Mutated Metastatic Breast Cancer Market to Expand Significantly by 2034, States DelveInsight Report | Sanofi, Sun Pharma, Zenopharm, Arvinas, Sermonix Pharma, H3 Biomedicine, Radius Pharma - Barchart.com
How does Arvinas Inc. generate profit in a changing economyMaximize returns with strategic trading plans - jammulinksnews.com
Why Arvinas Inc. stock attracts strong analyst attentionReversal Alert Based on RSI Indicator Confirmed - beatles.ru
Key External Factors That Drive Arvinas Inc. Stock Price MovementsFree Elite Traders Group - metal.it
What markets is Arvinas Inc. expanding into Is ESTA stock a good long term investment optionExceptional gains - jammulinksnews.com
How Resilient Is Arvinas Inc. Stock During Economic Downturns10x Return With Managed Risk - metal.it
What are the technical indicators suggesting about Arvinas Inc.Breakthrough stock performance - jammulinksnews.com
What are the latest earnings results for Arvinas Inc.Skyrocketing investment returns - jammulinksnews.com
What is the dividend policy of Arvinas Inc. stockGet real-time alerts on top stocks - jammulinksnews.com
Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat
What drives Arvinas Inc. stock priceFree Trend-Following Techniques - PrintWeekIndia
What analysts say about Arvinas Inc. stockLightning-fast growth - Autocar Professional
How high can Arvinas Inc. stock price go in 2025Skyrocketing investment returns - jammulinksnews.com
Is Arvinas Inc. a good long term investmentFree Buy/Sell Signal Notifications - Autocar Professional
Arvinas, Inc. (ARVN): A Bull Case Theory - Insider Monkey
Arvinas Inc. Stock Analysis and ForecastPhenomenal trading returns - Autocar Professional
Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment - MSN
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):